QTRX

Quanterix

Fundamental data last updated:March 2, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical Devices

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

1

Business Summary

Quanterix develops and sells ultra-sensitive digital immunoassay platforms used to detect biomarkers in blood and other biological samples. Its products are primarily utilized in life sciences research and diagnostics to enable earlier and more precise disease detection.

 


Analyze QTRX on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$305

Forward P/E

-

PEG

-

PRICE TO SALES

2.1

PRICE TO BOOK

1

EV / EBITDA

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$2.34

Next Year EPS Growth Estimate

-$1.41

Next Year Revenue Growth Estimate

27.30%

Return on Equity (ROE)

-30.40%

FREE CASH FLOW

Operating Margin

-78.10%

Debt-to-Equity

0.1

Piotroski F-Score

Altman Z-Score

Return on Invested Capital (ROIC)

Current Ratio

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze QTRX on TradingView

Gainseekers Quantitative Analysis

Summary

Quanterix is a Nasdaq-listed medical devices company with a market capitalization of $305 million and trades at a price-to-sales ratio of 2.1 and price-to-book ratio of 1. The company is currently unprofitable, reporting EPS of -$2.34, a return on equity of -30.40%, and an operating margin of -78.10%. Sales are expected to grow 27.30% next year, with EPS improving to an estimated -$1.41, and the next earnings report is in 1 day.

AI Exposure / Tech Reliance

As a medical devices company, Quanterix operates in a technology-driven segment of healthcare, where innovation and advanced platforms are central to its business model. Its growth outlook is tied to continued adoption of its technology within clinical and research settings.

The Bull Case

The company is projected to deliver strong sales growth of 27.30% next year, alongside an improvement in EPS from -$2.34 to an estimated -$1.41. It maintains low leverage with a debt-to-equity ratio of 0.1 and has high institutional ownership at 83.70%, suggesting support from professional investors.

The Bear Case

Quanterix remains deeply unprofitable, with a -78.10% operating margin and -30.40% return on equity, indicating significant operational challenges. Short interest stands at 8.10% of float, and there are no current earnings or forward P/E metrics, reflecting continued losses and uncertainty.

Market Sentiment & Smart Money

Short Interest %

8.10%

Analyst Consensus

3

Average Analyst Price Target

$7.33

Institutional Ownership %

83.70%

1-Year Beta

Insider Buying % (6 Mo)

Distance to 52-Week High

Distance to 52-Week Low

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.